scholarly journals Neonatal thrombocytopenia: A review. I. Definitions, differential diagnosis, causes, immune thrombocytopenia

2021 ◽  
Vol 119 (3) ◽  
2022 ◽  
Author(s):  
Florian Point ◽  
Louis Terriou ◽  
Thameur Rakza ◽  
Elodie Drumez ◽  
Gauthier Alluin ◽  
...  

Author(s):  
V.M. Dudnyk ◽  
O.I. Izyumets ◽  
V. H. Furman ◽  
O. V. Kutsak ◽  
O.O. Stetsun

Annotation. The aim of the study was to analyze with the help of literature data the features of the clinical course of immune thrombocytopenia, to monitor the mechanisms of reactions, as well as to reproduce them on their own observation. Features of clinical course and differential diagnosis of immune thrombocytopenia are described. It is established that the main manifestation of this pathology is hemorrhagic syndrome, accompanied by skin hemorrhages, bleeding, possible hepatosplenomegaly, jaundice. Detection of antiplatelet antibodies is used to confirm the diagnosis.


2006 ◽  
Vol 26 (01) ◽  
pp. 72-74 ◽  
Author(s):  
F. Boehlen

SummaryThrombocytopenia is observed in 6 to 15% of pregnant women at the end of pregnancy, and is usually moderate. Gestational thrombocytopenia (defined as a mild thrombocytopenia, occurring during the 3rd trimester with spontaneous resolution postpartum and no neonatal thrombocytopenia) is the most common cause of thrombocytopenia during pregnancy but a low platelet can also be associated with several diseases, either pregnancy specific or not, such as preeclampsia, HELLP syndrome, or idiopathic thrombocytopenic purpura (ITP). The differential diagnosis between ITP and gestational thrombocytopenia is clinically important with regard to the fetus, due to the risk of neonatal thrombocytopenia. However, this differential diagnosis is very difficult during pregnancy.Thrombocytopenia which need to be investigated are the following: thrombocytopenia known before pregnancy, thrombocytopenia occurring during the 1st and 2nd trimester, platelet count < 75 G/l in the 3rd trimester or thrombocytopenia in case of pregnancy with complications. Investigations have to be discussed in function of history and clinical examination, gestational age and severity of thrombocytopenia.No treatment is required in case of gestational thrombocytopenia. There are few data to distinguish management of ITP between pregnant and non-pregnant women but management is different because of the potential adverse effects of the treatment for the woman and/or the fetus, the requirement for a good hemostasis at delivery and the risk of neonatal hemorrhage. One important problem is that it is not possible to predict the risk of neonatal thrombocytopenia in babies born from women with ITP.


Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 2171-2171
Author(s):  
Zhongbo Hu ◽  
William Slayton ◽  
Lisa M. Rimsza ◽  
Martha Sola-Visner

Abstract Background: Thrombocytopenia is a frequent problem in sick neonates. Neonatal megakaryocytes (Mks) are smaller and of lower ploidy than adult Mks, and it has been hypothesized that this may represent a limitation in the ability of neonates to respond to thrombocytopenia. However, the study of megakaryopoiesis in sick thrombocytopenic neonates is intrinsically difficult, and has been further hampered by the lack of animal models. Objective: We generated a murine model of immune neonatal thrombocytopenia to test the hypothesis that neonates have a developmental deficiency in the ability to increase platelet production. Design/Methods: Neonatal thrombocytopenia was induced by injecting a commercially available anti-platelet antibody (MWReg30) into pregnant C57BL/6 mice. The antibody was administered daily by tail vein injection, starting on gestation day 12.5. Healthy non-pregnant adults were similarly treated to establish adult responses. On the first day of life, pups were bled by intracardiac puncture and complete blood counts were obtained on an automated cell counter. Livers, spleens and femoral bones were isolated, fixed, and immunohistochemically stained with anti-vWF antibody to highlight the Mks. Mks were then quantified and their diameters measured using an eyepiece reticle and an eyepiece micrometer, respectively. Results: Results are displayed as mean±SEM in Table 1. As shown, both newborn and adult thrombocytopenic mice had platelet counts approximately 1/3 of the normal mean for age. The main site of megakaryopoiesis was the liver (Liv) in newborn vs. the bone marrow (BM) in adult mice. As in human neonates, Mks in newborn pups were significantly smaller than in adult mice. The response to thrombocytopenia was different in newborn compared to adult mice: While the adults doubled the number of Mks in BM and spleen (Spl), newborn mice only exhibited a small increase in the diameter of their hepatic Mks, which did not reach normal adult size. To account for the combined contribution of changes in size and number, these measurements were multiplied to give an estimate of Mk "mass", expressed in arbitrary units. Overall, pups did not change their Mk mass in response to thrombocytopenia, while adult mice approximately doubled it. Conclusions: Newborn mice do not significantly increase their Mk mass in response to immune thrombocytopenia, suggesting that neonates have a developmental limitation in their ability to increase platelet production. Table 1. Megakaryocyte number, size, and mass Newborn mice Adult mice Control(n=25) Thrombo.(n=19) Control(n=14) Thrombo.(n=12) Plt, platelet; #, number; D., diameter; †, mean of 8 normal and 10 thrombocytopenic newborn samples; * p<0.05 vs. age-matched controls; **p<0.0001 vs. age-matched controls. Plt. count(×109/L) 711.4±23.2 292.0±18.6** 1298.2±46.0 418.1±71.6** Mk#(BM, /250 μ2)† 0.25±0.05 0.25±0.03 4.57±0.26 8.12±0.46** Mk#(Liv, /250 μ2) 1.70±0.13 1.88±0.12 0 0 Mk#(Spl, /250 μ2) 0.72±0.11 0.68±0.07 0.63±0.15 1.35±0.33* Mk D.(BM, μ) 14.06±1.08 15.59±0.43 20.80±0.41 20.53±0.40 Mk D.(Liv, μ) 15.76±0.12 17.55±0.28** Mk D.(Spl, μ) 15.04±0.38 15.92±0.37 21.71±0.47 22.55±0.67 Mk mass(BM) 3.41±0.78 3.59±0.52 97.48±4.31 167.43±10.73** Mk mass(Liv) 26.88±2.09 29.06±2.74 Mk mass(Spl) 10.78±1.95 10.49±1.32 14.15±3.63 32.32±6.07*


Author(s):  
Mohamad Hosein Lookzadeh ◽  
Seyed Reza Mirjalili ◽  
Sedigheh Ekraminasab

Neonatal thrombocytopenia (NT) is a common hemostatic abnormalitiy among newborn in the NICU, which increases with the degree of prematurity. It is well documented that this disease has a large range of feasible etiologies. Prematurity, early and late-onset sepsis and asphyxia are the most usual causes of NT. Moreover, FNAIT is the major risk for intracranial hemorrhage in the fetus or newborn. Here, we reviewed the causes for NT, in both newborns and mothers. We demonstrated the factors associated with NT in the newborn including placental insufficiency, fetal and neonatal alloimmune thrombocytopenia (FNAIT), prematurity, sepsis, and asphyxia. The causes of thrombocytopenia in pregnant women and its impact on newborns were also described. This review showed that gestational thrombocytopenia was the most common cause of thrombocytopenia with an incidence of 70-80%, followed by preeclampsia, HELLP and ITP. But neonates born to mothers with immune thrombocytopenia (ITP) had a higher risk for NT and hemorrhagic problems. In ITP, neonatal platelets are destroyed by maternal autoantibodies. We reviewed the causes of thrombocytopenia in neonates and mothers in two groups of immune and nonimmune factors. However, it seems that immunological factors are the most severe form of NT. However, it is necessary to separate NT etiology for differential diagnosis.


2014 ◽  
Vol 99 (5) ◽  
pp. 570-576 ◽  
Author(s):  
Koji Kawaguchi ◽  
Kousaku Matsubara ◽  
Toshiro Takafuta ◽  
Isaku Shinzato ◽  
Yasuhiro Tanaka ◽  
...  

2017 ◽  
Vol 2017 ◽  
pp. 1-4 ◽  
Author(s):  
Hasan Tarkan Ikizoglu ◽  
Inci Ayan ◽  
Fatma Tokat ◽  
Tulay Tecimer ◽  
Gonca Topuzlu Tekant

Thrombocytopenia is a frequent finding in patients with solid tumors. It is usually caused by bone marrow infiltration or by myelosuppression due to anticancer therapy; however immune thrombocytopenia (ITP) associated with solid tumors is rare. Neuroblastoma is the most common extracranial solid tumor in children. Here we report the case of a two-year-nine-month-old patient with adrenal neuroblastoma who presented with ITP. Paraneoplastic ITP was considered in the differential diagnosis. Bone marrow infiltration and other causes of thrombocytopenia were excluded and the patient was treated with intravenous immunoglobulin and tumor resection. Platelet count increased rapidly after surgery and complete remission of ITP was achieved.


Author(s):  
O.M. Naumchik ◽  
◽  
Iu.V. Davydova ◽  
A.Yu. Limanska ◽  
◽  
...  

Purpose — to create an algorithm for early diagnosis and differential diagnosis of conditions accompanied by thrombocytopenia (TP) during pregnancy, as well as an algorithm for the treatment of immune thrombocytopenia during pregnancy based on analysis of clinical, laboratory data and obstetric and perinatal results of such pregnant women. Materials and methods. We analyzed 155 histories of pregnancy and childbirth of women with TP, who underwent inpatient treatment and/or gave childbirth in the obstetric clinic of the State Institution «Institute of Pediatrics, Obstetrics and Gynecology named after Academician O.M. Lukyanova NAMS of Ukraine» from January 2008 to August 2018. According to the inclusion criteria, 111 histories were selected for further analysis. Pregnant women are divided according to the etiological principle of TP into three groups: with gestational thrombocytopenia, immune thrombocytopenia, secondary thrombocytopenia. The first group included 32 women (28.8%), the second — 65 (55.6%), the third — 14 (12.6%). During the selected period of time there were 99 births, 100 babies were born, 1 twin birth. Results and conclusions. The number of platelets progressively decreases during pregnancy with a minimum in childbirth. The algorithm of examination, the decision on the initiation or intensification of treatment, the choice of monitoring tactics for TP during pregnancy, the calculation of obstetric and perinatal risks, preparation for childbirth and the choice of method depend on the cause of TP and differ significantly. Developed «Algorithm for diagnosis and differential diagnosis in the detection of thrombocytopenia during pregnancy» and «Algorithm for the treatment of immune thrombocytopenia during pregnancy» are aimed at the prevention of obstetric and perinatal complications in pregnant women with thrombocytopenia. The research was carried out in accordance with the principles of the Helsinki declaration. The study protocol was approved by the Local Ethics Committee of an participating institution. The informed consent of the patient was obtained for conducting the studies. No conflict of interest was declared by the authors. Key words: thrombocytopenia, pregnancy, diagnostic algorithm, treatment algorithm.


2019 ◽  
Vol 98 (4) ◽  
pp. 62-71
Author(s):  
E.V. Suntsova ◽  
◽  
D.D. Baydildina ◽  
I.I. Kalinina ◽  
U.N. Petrova ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document